Background, clinical features and treatment of attention deficit hyperactivity disorder in children

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 14, 2013, Pages 1885-1906

  Warikoo, Nisha ^a   Faraone, Stephen V ^b  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

ADHD; Non stimulants; Stimulants; Treatment

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEBUTAMONE; AMPHETAMINE; ARIPIPRAZOLE; ATOMOXETINE; CENTRAL STIMULANT AGENT; CLONIDINE; DESIPRAMINE; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; DONEPEZIL; ESSENTIAL FATTY ACID; GUANFACINE; HYPERICUM PERFORATUM EXTRACT; IMIPRAMINE; LISDEXAMFETAMINE; METHAMPHETAMINE; METHYLPHENIDATE; MODAFINIL; MONOAMINE OXIDASE INHIBITOR; NEUROTRANSMITTER; NORTRIPTYLINE; OMEGA 3 FATTY ACID; PLACEBO; PROCENTRA; RISPERIDONE; STRATERRAL; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADD ON THERAPY; ALGORITHM; ALTERNATIVE MEDICINE; ANGIONEUROTIC EDEMA; ATTENTION DEFICIT DISORDER; AUTISM; BLOOD PRESSURE; BRADYCARDIA; CARDIOVASCULAR EFFECT; CLINICAL EVALUATION; CLINICAL FEATURE; COMORBIDITY; CONSTIPATION; CONTACT SENSITIZATION; DECREASED APPETITE; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DROWSINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; ENVIRONMENTAL FACTOR; EPILEPSY; EVENING DOSAGE; GINKGO BILOBA; GROWTH; GROWTH DISORDER; HEADACHE; HEART RATE; HUMAN; HYPOTENSION; INSOMNIA; IRRITABILITY; LIVER INJURY; LOW DRUG DOSE; MAINTENANCE CHEMOTHERAPY; MANIA; MEDICATION THERAPY MANAGEMENT; MENTAL INSTABILITY; MOLECULAR GENETICS; MORNING DOSAGE; NAUSEA; NEUROBIOLOGY; NEUROIMAGING; NONHUMAN; PRACTICE GUIDELINE; PREVALENCE; PSYCHOSIS; PULSE RATE; RASH; REVIEW; RISK FACTOR; SEDATION; SIDE EFFECT; SOMNOLENCE; SUBSTANCE ABUSE; SUDDEN CARDIAC DEATH; SUDDEN DEATH; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SYSTOLIC BLOOD PRESSURE; TIC; TITRIMETRY; TREATMENT FAILURE; URTICARIA; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; HUMANS;

EID: 84884258930     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.818977     Document Type: Review

References (134)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV-TR. American Psychiatric Association, Washington DC; 2000
2. Larson K, Russ SA, Kahn RS, et al. Patterns of comorbidity, functioning, and service use for US children with ADHD, 2007. Pediatrics 2011;127:462-70
3. Bird H. The diagnostic classification, epidemiology and cross-cultural validity of ADHD. In: Jensen PS, Cooper JR., editors, Attention deficit hyperactivity disorder: State of the science: Best practices. Civic Research Institute, Kingston, NJ; 2002
4. Faraone SV, Sergeant J, Gillberg C, et al. The Worldwide prevalence of ADHD: Is it an American condition̈World Psychiatry 2003;2:104-13
5. Rappley MD. Clinical practice. Attention deficit-hyperactivity disorder. N Engl J Med 2005;352:165-73
6. Polanczyk G, de Lima MS, Horta BL, et al. The worldwide prevalence of ADHD: A systematic review and meta-regression analysis. Am J Psychiatry 2007;164:942-8
7. Gordon M, Antshel K, Faraone S, et al. Symptoms Versus Impairment: The Case for Respecting DSM-IV's Criterion D. J Atten Disord 2006;9:465-75
8. Barbaresi WJ, Katusic SK, Colligan RC, et al. How common is attention-deficit/ hyperactivity disorder̈Incidence in a population-based birth cohort in Rochester, Minn. Arch Pediatr Adolesc Med 2002;156:217-24
9. (CDC), C.f.D.C.a.P. Increasing prevalence of parent-reported attentiondeficit/ hyperactivity disorder among children -United States, 2003 and 2007. MMWR Morb Mortal Wkly Rep 2010;59:1439-43
10. Wolraich ML, Wibbelsman CJ, Brown TE, et al. Attention-deficit/ hyperactivity disorder among adolescents: A review of the diagnosis, treatment, and clinical implications. Pediatrics 2005;115:1734-46
11. Faraone SV, Biederman J, Lehman BK, et al. Intellectual performance and school failure in children with attention deficit hyperactivity disorder and in their siblings. J Abnorm Psychol 1993;102:616-23
12. Barbaresi WJ, Katusic SK, Colligan RC, et al. Long-term school outcomes for children with attention-deficit/ hyperactivity disorder: A population-based perspective. J Dev Behav Pediatr 2007;28:265-73
13. Biederman J, Mick E, Faraone SV. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: Impact of remission definition and symptom type. Am J Psychiatry 2000;157:816-18
14. Krueger M, Kendall J. Descriptions of self: An exploratory study of adolescents with ADHD. J Child Adolesc Psychiatr Nurs 2001;14:61-72
15. Frazier TW, Youngstrom EA, Glutting JJ, et al. ADHD and achievement: Meta-analysis of the child, adolescent, and adult literatures and a concomitant study with college students. J Learn Disabil 2007;40:49-65
16. Faraone SV, Biederman J, Mick E. The age dependent decline of attentiondeficit/ hyperactivity disorder: A meta-analysis of follow-up studies. Psychol Med 2006;36:159-65
17. Diagnosis Of Attention-deficit Hyperactivity Disorder - Redirect. Rockville, MD Available from: [Last accessed May 2008
18. Diagnosis of attention-deficit/ hyperactivity disorder - Redirect. Agency for Healthcare Research and Quality, Rockville, MD; 2008. Available from: Http://www.ahrq. gov/redirects/adhdd [Last accessed May 2008] 18. Biederman J, Newcorn J, Sprich S. Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry 1991;148:564-77
19. Faraone SV, Biederman J, Wozniak J. Examining the comorbidity between attention deficit hyperactivity disorder and bipolar I disorder: A meta-analysis of family genetic studies. Am J Psychiatry 2012;16:1256-66
20. Mulligan A, Anney RJ, O'Regan M, et al. Autism symptoms in Attentiondeficit/ hyperactivity disorder: A familial trait which correlates with conduct, oppositional defiant, language and motor disorders. J Autism Dev Disord 2009;39:197-209
21. Bird HR, Canino G, Rubio-Stipec M, et al. Estimates of the prevalence of childhood maladjustment in a community survey in Puerto Rico: The use of combined measures. Arch Gen Psychiatry 1988;45:1120-6
22. Kieling C, Goncalves RR, Tannock R, et al. Neurobiology of attention deficit hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 2008;17:285-307
23. Swanson JM, Kinsbourne M, Nigg J, et al. Etiologic subtypes of attentiondeficit/ hyperactivity disorder: Brain imaging, molecular genetic and environmental factors and the dopamine hypothesis. Neuropsychol Rev 2007;17:39-59
24. Tripp G, Wickens Jr.. Neurobiology of ADHD. Neuropharmacology 2009;57:579-89
25. Swanson JM, Hinshaw SP, LE A, et al. Clinical and cognitive definitions of attention deficit in children in attentiondeficit/ hyperactivity disorder. In: Posner M., editors, Guilford Press, New York; 2004
26. Valera E, Faraone SV, Murray K, et al. Meta-analysis of structural imaging findings in attention-deficit/hyperactivity disorder. Biol Psychiatry 2007;61:1361-9
27. Castellanos FX, Lee PP, Sharp W, et al. Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/ hyperactivity disorder. JAMA 2002;288:1740-8
28. Himelstein J, Newcorn JH, Halperin JM. The neurobiology of attention-deficit hyperactivity disorder. Front Biosci 2000;5:D461-78
29. Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry 2010;19:353-64
30. Seiden LS, Sabol KE, Ricaurte GA. Amphetamine: Effects on catecholamine systems and behavior. Annu Rev Pharmacol Toxicol 1993;33:639-77
31. Descarries L, Lemay B, Doucet G, et al. Regional and laminar density of the dopamine innervation in adult rat cerebral cortex. Neuroscience 1987;21:807-24
32. Volkow ND, Fowler JS, Wang G, et al. Mechanism of action of methylphenidate: Insights from PET imaging studies. J Atten Disord 2002;6:S31-43
33. Berridge CW, Devilbiss D.M, Andrzejewski ME, et al. Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biol Psychiatry 2006;60:1111-20
34. Faraone SV, Wilens TE. Effect of stimulant medications on later substance use and the potential for misuse, abuse, and diversion. J Clin Psychiatry 2007;68:15-22
35. Gamo NJ, Wang M, Arnsten AF. Methylphenidate and atomoxetine enhance prefrontal function through alpha2-adrenergic and dopamine D1 receptors. J Am Acad Child Adolesc Psychiatry 2010;49:1011-23
36. Thomason C, Michelson D. Atomoxetine-treatment of attention deficit hyperactivity disorder: Beyond stimulants. Drugs Today (Barc) 2004;40:465-73
37. Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002;27:699-711
38. Biederman J, Melmed RD, Patel A, et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/ hyperactivity disorder. Pediatrics 2008;121:73-84
39. Scassellati C, Bonvicini C, Faraone SV, et al. Biomarkers and attention-deficit/ hyperactivity disorder: A systematic review and meta-analyses. J Am Acad Child Adolesc Psychiatry 2012;51:1003-19
40. Faraone S, Mick E. Molecular genetics of attention deficit hyperactivity disorder. Psychiatr Clin North Am 2010;33:159-80
41. Bergen SE, Gardner CO, Kendler KS. Age-related changes in heritability of behavioral phenotypes over adolescence and young adulthood: A meta-analysis. Twin Res Hum Genet 2007;10:423-33
42. Franke B, Faraone SV, Asherson P, et al. The genetics of attention deficit/ hyperactivity disorder in adults, a review. Mol Psychiatry 2012;17:960-87
43. Zhou K, Dempfle A, Arcos-Burgos M, et al. Meta-analysis of genome-wide linkage scans of attention deficit hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 2008;147B:1392-8
44. Neale B, Medland SE, Ripke S, et al. Meta-analysis of genome-wide association studies of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2010;49:884-97
45. Williams NM, Franke B, Mick E, et al. Genome-wide analysis of copy number variants in attention deficit/hyperactivity disorder confirms the role of rare variants and implicates duplications at 15q13.3. Am J Psychiatry 2012;169:195-204
46. Elia J, Glessner JT, Wang K, et al. Genome-wide copy number variation study associates metabotropic glutamate receptor gene networks with attention deficit hyperactivity disorder. Nat Genet 2012;44:78-84
47. Banerjee TD, Middleton F, Faraone SV. Environmental risk factors for attention-deficit hyperactivity disorder. Acta Pediatrica 2007;96:1269-74
48. Buschgens CJ, van Aken MA, Swinkels SH, et al. Differential family and peer environmental factors are related to severity and comorbidity in children with ADHD. J Neural Transm 2008;115:177-86
49. Biederman J, Faraone SV, Monuteaux MC. Differential effect of environmental adversity by gender: Rutter's index of adversity in a group of boys and girls with and without ADHD. Am J Psychiatry 2002;159:1556-62
50. Biederman J, Petty CR, Bhide PG, et al. Does exposure to maternal smoking during pregnancy affect the clinical features of ADHD̈Results from a controlled study. World J Biol Psychiatry 2012;13:60-4
51. Milberger S, Biederman J, Faraone SV, et al. Pregnancy, delivery and infancy complications and attention deficit hyperactivity disorder: Issues of gene-environment interaction. Biol Psychiatry 1997;41:65-75
52. American Psychiatric Association. Attention-deficit and disruptive behavior disorders. In: Diagnostic and statistical manual of mental disorders: DSM-IV TR. American Psychiatric Publishing, Washington DC; 2013
53. Wolraich M, Brown L, Brown RT, et al. ADHD: Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 2011;128:1007-22
54. Faraone SV, Kunwar A, Adamson J, et al. Personality traits among ADHD adults: Implications of late-onset and subthreshold diagnoses. Psychol Med 2009;39:685-93
55. Faraone SV, Wilens TE, Petty C, et al. Substance use among ADHD adults: Implications of late onset and subthreshold diagnoses. Am J Addict 2007;16:24-34
56. Faraone SV, Biederman J, Spencer TJ, et al. Diagnosing Adult attention deficit hyperactivity disorder: Are Late Onset and Subthreshold Diagnoses Valid̈Am J Psychiatry 2006;163:1720-9
57. Faraone SV, Biederman J, Doyle AE, et al. Neuropsychological Studies of Late Onset and Subthreshold Diagnoses of Adult ADHD. Biol Psychiatry 2006;60:1081-7
58. Antshel KM, Faraone SV, Maglione K, et al. Is adult attention deficit hyperactivity disorder a valid diagnosis in the presence of high IQ̈Psychol Med 2009;39:1325-35
59. Antshel KM, Faraone SV, Maglione K, et al. Executive functioning in high-IQ adults with ADHD. Psychol Med 2010;40:1909-18
60. Antshel KM, Faraone SV, Maglione K, et al. Temporal stability of ADHD in the high-IQ population: Results from the MGH Longitudinal Family Studies of ADHD. J Am Acad Child Adolesc Psychiatry 2008;47:817-25
61. Antshel KM, Faraone SV, Stallone K, et al. Is attention deficit hyperactivity disorder a valid diagnosis in the presence of high IQ̈J Child Psychol Psychiatry 2007;48:687-94
62. Kaplan G, Newcorn JH. Pharmacotherapy for child and adolescent attention-deficit hyperactivity disorder. Pediatr Clin North Am 2011;58:99-120
63. Background, clinical features and treatment of attention deficit hyperactivity disorder in children Expert Opin. Pharmacother. (2013) 14(14) 1903
64. Marrow MA, Garland E, Wright J, et al. Influence of relative age in diagnosis and treatment of attention-deficit/ hyperactivity disorder in children. Can Med Assoc J 2012;1-8
65. Biederman J, Petty CR, Woodworth KY, et al. Adult outcome of attention-deficit/ hyperactivity disorder: A controlled 16-year follow-up study. J Clin Psychiatry 2012;73:941-50
66. Attention-Deficit Hyperactivity Disorder (ADHD). Psychiatry, A.A.o.C.a.A. 2011. Available from: Http://eguideline. guidelinecentral.com/i/55268#
67. Faraone SV, Biederman J, Zimmerman B. An analysis of patient adherence to treatment during a 1-year, open-label study of OROS methylphenidate in children with ADHD. J Atten Disord 2007;11:157-66
68. MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/ hyperactivity disorder. Pediatrics 2004;113:754-61
69. American Academy of Child and Adolescent Psychiatry. Practice parameter on the use of psychotropic medication in children and adolescents. J Am Acad Child Adolesc Psychiatry 2009;48:961-73
70. Lavigne JV, Dulcan MK, LeBailly SA, et al. Can parent reports serve as a proxy for teacher ratings in medication management of attention-deficit hyperactivity disorder̈J Dev Behav Pediatr 2012;33:336-42
71. Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007;46:894-921
72. Pediatrics, A.A.o., ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention- Deficit/Hyperactivity Disorder in Children and Adolescents. Process of Care Supplemental Appendix. 2011
73. Faraone SV, Biederman J, Spencer TJ, et al. Comparing the efficacy of medications for ADHD using meta-analysis. Med Gen Med E J 2006;8:4
74. Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry 2010;71:754-63
75. Kim Y, Shin MS, Kim JW, et al. Neurocognitive effects of switching from methylphenidate-IR to OROS-methylphenidate in children with ADHD. Hum Psychopharmacol 2009;24:95-102
76. Wolraich ML, Lambert W, Doffing MA, et al. Psychometric properties of the Vanderbilt ADHD diagnostic parent rating scale in a referred population. J Pediatr Psychol 2003;28:559-67
77. Rostain A, Jensen PS, Connor DF, et al. Toward quality care in ADHD: Defining the goals of treatment. J Atten Disord 2013; Epub ahead of print
78. Greenhill LL, Abikoff HB, Arnold LE, et al. Medication treatment strategies in the MTA Study: Relevance to clinicians and researchers. J Am Acad Child Adolesc Psychiatry 1996;35:1304-13
79. Prasad S, Steer C. Switching from neurostimulant therapy to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder : Clinical approaches and review of current available evidence. Paediatr Drugs 2008;10:39-47
80. Sallee F, McGough J, Wigal T, et al. Guanfacine extended release in children and adolescents with attention-deficit/ hyperactivity disorder: A placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2009;48:155-65
81. Kollins SH, Jain R, Brams M, et al. Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD. Pediatrics 2011;127:1406-13
82. Palumbo DR, Sallee FR, Pelham WE Jr., et al. Clonidine for attention-deficit/ hyperactivity disorder: I. Efficacy and tolerability outcomes. J Am Acad Child Adolesc Psychiatry 2008;47:180-8
83. Spencer TJ, Greenbaum M, Ginsberg LD, et al. Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/ hyperactivity disorder. J Child Adolesc Psychopharmacol 2009;19:501-10
84. Wilens TE, Bukstein O, Brams M, et al. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2012;51:74-85
85. Wilens TE, Hammerness P, Utzinger L, et al. An open study of adjunct OROS-methylphenidate in children and adolescents who are atomoxetine partial responders: I. Effectiveness. J Child Adolesc Psychopharmacol 2009;19:485-92
86. Faraone SV, Biederman J, Monuteaux M, et al. Long-term effects of extended-release mixed amphetamine salts treatment of attention- deficit/ hyperactivity disorder on growth. J Child Adolesc Psychopharmacol 2005;15:191-202
87. Faraone SV, Giefer EE. Long-term effects of methylphenidate transdermal delivery system treatment of ADHD on growth. J Am Acad Child Adolesc Psychiatry 2007;46:1138-47
88. Faraone SV, Spencer TJ, Kollins SH, et al. Effects of lisdexamfetamine dimesylate treatment for ADHD on growth. J Am Acad Child Adolesc Psychiatry 2010;49:24-32
89. Faraone SV, Biederman J, Morley CP, et al. Effect of stimulants on height and weight: A review of the literature. J Am Acad Child Adolesc Psychiatry 2008;47:994-1009
90. Klein R, Mannuzza S. Hyperactive boys almost grown up: III. Methylphenidate effects on ultimate height. Arch Gen Psychiatry 1988;45:1131-4
91. Safer D, Allen R, Barr E. Growth rebound after termination of stimulant drugs. J Pediatr 1975;86:113-16
92. Molina BS, Hinshaw SP, Swanson JM, et al. MTA at 8 Years: Prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry 2009;48:484-500
93. Jensen PS, Arnold LE, Swanson JM, et al. 3-Year Follow-up of the NIMH MTA Study. J Am Acad Child Adolesc Psychiatry 2007;46:989-1002
94. Garnock-Jones KP, Keating GM. Atomoxetine: A review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs 2009;11:203-26
95. Scahill L. Alpha-2 adrenergic agonists in children with inattention, hyperactivity and impulsiveness. CNS Drugs 2009;23(Suppl1):43-9
96. Barrickman L, Perry P, Allen A, et al. Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1995;34:649-57
97. Jafarinia M, Mohammadi MR, Modabbernia A, et al. Bupropion versus methylphenidate in the treatment of children with attention-deficit/ hyperactivity disorder: Randomized double-blind study. Hum Psychopharmacol 2012;27:411-18
98. Jadad AR, Boyle M, Cunningham C, et al. Treatment of attention-deficit/ hyperactivity disorder. Evid Rep Technol Assess (Summ) 1999;11:1-341
99. Wilens T, Biederman J, Baldessarini R, et al. Cardiovascular effects of therapeutic doses of tricyclic antidepressants in children and adolescents. J Am Acad Child Adolesc Psychiatry 1996;35:1491-501
100. Kahbazi M, Ghoreishi A, Rahiminejad F, et al. A randomized, double-blind and placebo-controlled trial of modafinil in children and adolescents with attention deficit and hyperactivity disorder. Psychiatry Res 2009;168:234-7
101. Weber W, Vander Stoep A, McCarty RL, et al. Hypericum perforatum (St John's Wort) for attention-deficit/hyperactivity disorder in children and adolescents a randomized controlled trial. J Am Med Assoc 2008;229:2633-41
102. Wilens T, Waxmonsk J, Scott M, et al. An open trial of adjunctive donepezil in attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2005;15:947-55
103. Gillies D, Sinn J, Lad SS, et al. Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev 2012;7:CD007986
104. Bloch MH, Qawasmi A. Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/ hyperactivity disorder symptomatology: Systematic review and meta-analysis. J Am Acad Child Adolesc Psychiatry 2011;50:991-1000
105. Salehi B, Imani R, Mohammadi MR, et al. Ginkgo biloba for attention-deficit/ hyperactivity disorder in children and adolescents: A double blind, randomized controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:76-80
106. Lan Y, Zhang LL, Luo R. Attention deficit hyperactivity disorder in children: Comparative efficacy of traditional Chinese medicine and methylphenidate. J Int Med Res 2009;37:939-48
107. Nigg JT, Lewis K, Edinger T, et al. Meta-analysis of attention-deficit/ hyperactivity disorder or attention-deficit/ hyperactivity disorder symptoms, restriction diet, and synthetic food color additives. J Am Acad Child Adolesc Psychiatry 2012;51:86-97
108. Biederman J, Spencer TJ, Monuteaux MC, et al. A naturalistic 10-year prospective study of height and weight in children with attention-deficit hyperactivity disorder grown up: Sex and treatment effects. J Pediatr 2010;157:635-40
109. Cooper WO, Habel LA, Sox C, et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med 2011;365:1896-904
110. Schelleman H, Bilker WB, Strom BL, et al. Cardiovascular events and death in children exposed and unexposed to ADHD agents. Pediatrics 2011;127:1102-10
111. Association, A.A.o.P.A.H. American Academy of Pediatrics/American Heart Association clarification of statement on cardiovascular evaluation and monitoring of children and adolescents with heart disease receiving medications for ADHD: May 16, 2008. J Dev Behav Pediatr 2008;29:335
112. Biederman J, Petty CR, Hammerness P, et al. Cigarette smoking as a risk factor for other substance misuse: 10-year study of individuals with and without attention-deficit hyperactivity disorder. Br J Psychiatry 2012;201:207-14
113. Biederman J, Petty CR, Monuteaux MC, et al. Familial risk analysis of the association between attention-deficit/ hyperactivity disorder and psychoactive substance use disorder in female adolescents: A controlled study. J Child Psychol Psychiatry 2009;50:352-8
114. Biederman J, Petty CR, Wilens TE, et al. Familial risk analyses of attention deficit hyperactivity disorder and substance use disorders. Am J Psychiatry 2008;165:107-15
115. Wilens T, Faraone SV, Biederman J, et al. Does stimulant therapy of attention deficit hyperactivity disorder beget later substance abusëa meta-analytic review of the literature. Pediatrics 2003;111:179-85
116. Bloch MH, Panza KE, Landeros-Weisenberger A, et al. Metaanalysis: Treatment of attention-deficit/ hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adolesc Psychiatry 2009;48:884-93
117. Bangs ME, Tauscher-Wisniewski S, Polzer J, et al. Meta-analysis of suicide-related behavior events in patients treated with atomoxetine. J Am Acad Child Adolesc Psychiatry 2008;47:209-18
118. Instances of death in connection with Straterra treatment. 2010. Available from: Http://jannel.se/ StratteraDeath5.pdf
119. Greenhill L, Kollins S, Abikoff H, et al. Efficacy and Safety of Immediate-Release Methylphenidate Treatment for Preschoolers With ADHD. J Am Acad Child Adolesc Psychiatry 2006;45:1284-93
120. Gonzalez-Heydrich J, Dodds A, Whitney J, et al. Psychiatric disorders and behavioral characteristics of pediatric patients with epilepsy and ADHD. Epilepsy Behav 2007;10:384-8
121. Parisi P, Moavero R, Verrotti A, et al. Attention deficit hyperactivity disorder in children with epilepsy. Brain Dev 2010;32:10-16
122. Mahajan R, Bernal MP, Panzer R, et al. Clinical practice pathways for evaluation and medication choice for attentiondeficit/ hyperactivity disorder symptoms in autism spectrum disorders. Pediatrics 2012;130(Suppl2):S125-38
123. Antshel KM, Faraone SV, Gordon M. Cognitive behavioral treatment outcomes in adolescent ADHD. J Atten Disord 2012. [Epub ahead of print
124. Zwi M, Jones H, Thorgaard C, et al. Parent training interventions for Attention Deficit Hyperactivity Disorder (ADHD) in children aged 5 to 18 years. Cochrane Database Syst Rev 2011(12):CD003018
125. MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/ hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry 1999;56:1073-86
126. Jensen PS, Hinshaw SP, Kraemer HC, et al. ADHD comorbidity findings from the MTA study: Comparing comorbid subgroups. J Am Acad Child Adolesc Psychiatry 2001;40:147-58
127. Charach A, Dashti B, Carson P, et al. Attention deficit hyperactivity disorder: Effectiveness of treatment in at-risk preschoolers; long-term effectiveness in all ages; and variability in prevalence, diagnosis, and treatment [Internet]. in AHRQ comparative effectiveness reviews. Agency for Healthcare Research and Quality (US); Rockville: 2011
128. Storebo OJ, Skoog M, Damm D, et al. Social skills training for Attention Deficit Hyperactivity Disorder (ADHD) in children aged 5 to 18 years. Cochrane Database Syst Rev 2011(12):CD008223
129. Jensen PS, Hinshaw SP, Swanson JM, et al. Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): Implications and applications for primary care providers. J Dev Behav Pediatr 2001;22:60-73
130. Sonuga-Barke EJ, Brandeis D, Cortese S, et al. Nonpharmacological interventions for ADHD: Systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments. Am J Psychiatry 2013;170:275-89
131. Mick E, McGough JJ, Middleton FA, et al. Genome-wide association study of blood pressure response to methylphenidate treatment of attentiondeficit/ hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:466-72
132. Mick E, Neale B, Middleton FA, et al. Genome-wide association study of response to methylphenidate in 187 children with attention-deficit/ hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 2008;147B:1412-18
133. Smoller JW, Craddock N, Kendler K, et al. Identification of risk loci with shared effects on five major psychiatric disorders: A genome-wide analysis. Lancet 2013;381:1371-9
134. Cichon S, Craddock N, Daly M, et al. Genomewide association studies: History, rationale, and prospects for psychiatric disorders. Am J Psychiatry 2009;166:540-56